Effects of inhaled budesonide on insulin sensitivity in nondiabetic patients with asthma and chronic obstructive pulmonary disease

Advances in Therapy

Volumn 24, Issue 3, 2007, Pages 560-570

  Canis, Recep ^a   Demirkok, Sevtap Sipahi ^b,c   Osar, Zeynep ^a   Balci, Huriye ^a   Can, Günay ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Asthma; COPD; Inhaled corticosteroid therapy; Insulin sensitivity

Indexed keywords

BUDESONIDE; C REACTIVE PROTEIN; GLUCOSE; INSULIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BODY MASS; CARBOHYDRATE METABOLISM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; POWDER INHALER; SMOKING; STATISTICAL ANALYSIS;

EID: 34548098396     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02848778     Document Type: Article

References (25)

1. Ankerst J, Persson G, Weibull E. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma. Pulm Pharmacol Ther. 2003;16:147-151.
2. Faul JF, Cormican LJ, Tormey V, Tormey W, Burke C. Deteriorating diabetic control associated with high-dose inhaled budesonide. Eur Respir J. 1999;14:242-243.
3. Kiviranta K, Turpeinen M. Effect of eight months of inhaled beclomethasone dipropionate and budesonide on carbohydrate metabolism in adults with asthma. Thorax. 1993;48:974-978.
4. Turpeinen M, Sorva R, Juntunen-Backman K. Changes in carbohydrate and lipid metabolism in children with asthma inhaling budesonide. J Allergy Clin Immunol. 1991;88:384-389.
5. Ebden P, McNally P, Samanta A, Fancourt GJ. The effects of high dose inhaled beclomethasone dipropionate on glucose and lipid profiles in normal and diet controlled diabetic subjects. Respir Med. 1989;83:289-291.
6. Kruszynska YT, Greenstone M, Home PD, Cooke NJ. Effect of high dose inhaled beclomethasone dipropionate on carbohydrate and lipid metabolism in normal subjects. Thorax. 1987;42:881-884.
7. Yernault JC, Leclercq R, Schandevyl W, Virasoro E, De Coster A, Copinschi G. The endocrinometabolic effects of beclomethasone dipropionate in asthmatic patients. Chest. 1977;71:698-702.
8. Rewers M, Zaccaro D, D'Agostino R, Haffner S, Saad MF. Insulin sensitivity, insulinemia, and coronary artery disease: the insulin resistance atherosclerosis study. Diabetes Care. 2004;27:781-787.
9. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334;952-958.
10. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M. Insulin sensitivity and atherosclerosis. Circulation. 1996;93:1809-1817.
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412-419.
12. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47:1643-1649.
13. American Diabetes Association. Clinical practice recommendations 2003. Diabetes Care. 2003;26(suppl 1):S1-S156.
14. Global Initiative for Asthma (GINA). Asthma Management and Prevention. Bethesda, Md: National Heart, Lung, and Blood Institute; 2002. NIH Publication No. 96-3659A.
15. British Thoracic Society. British guideline on the management of asthma. Thorax. 2003;58(suppl 1):i1-i94.
16. National Heart, Lung, and Blood Institute/World Health Organization. NHLBI/WHO Workshop Report: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Global Initiative for Chronic Obstructive Lung Disease (GOLD). Bethesda, Md: NHLBI; 2004 (update).
17. Komshian H-Y, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care. 2000;23:171-175.
18. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1995;152:1107-1136.
19. Lentner C. Geigy Scientific Tables. Basel, Switzerland: Ciba-Geigy Ltd; 1982:178.
20. Emoto M, Nishizawa Y, Maekawa K, et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care. 1999;22:818-822.
21. Harrison TW, Tattersfield AE. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax. 2003;58:258-260.
22. Neville A, Palmer JBD, Gaddie J, May CS, Palmer KNV. Metabolic effects of salbutamol: comparison of aerosol and intravenous administration. BMJ. 1977;1:413-414.
23. Pinkney J. Clinical research methods in diabetes (Chapter 35). In: Pickup J, Williams G, eds. Textbook of Diabetes. Boston, Mass: Blackwell Science; 1997.
24. Rana JS, Mittleman MA, Sheikh J, Hu FB, Manson JE. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care. 2004;27:2478-2484.
25. Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52:812-817.